Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
Socinski MA, Waller CF, Idris T, Bondarenko I, Luft A, Beckmann K, Vishweswaramurthy A, Loganathan S, Donnelly C, Hummel MA, Shapiro R, Woods M, Rao A, Nayak VG, Ranganna G, Barve A. Socinski MA, et al. Among authors: rao a. Ther Adv Med Oncol. 2021 Nov 18;13:17588359211045845. doi: 10.1177/17588359211045845. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34819997 Free PMC article.
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study.
Blevins TC, Raiter Y, Sun B, Donnelly C, Shapiro R, Chullikana A, Rao A, Vashishta L, Ranganna G, Barve A. Blevins TC, et al. Among authors: rao a. BioDrugs. 2022 Nov;36(6):761-772. doi: 10.1007/s40259-022-00554-6. Epub 2022 Sep 17. BioDrugs. 2022. PMID: 36114990 Free PMC article. Clinical Trial.
Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
Sun B, Sengupta N, Rao A, Donnelly C, Waichale V, Roy AS, Ramaswamy S, Pathak D, Bowsher RR, Raiter Y, Aubonnet P, Barve A. Sun B, et al. Among authors: rao a. BMC Endocr Disord. 2021 Jun 26;21(1):129. doi: 10.1186/s12902-021-00797-4. BMC Endocr Disord. 2021. PMID: 34174848 Free PMC article. Clinical Trial.
A mutant ASXL1-EHMT complex contributes to heterochromatin dysfunction in clonal hematopoiesis and chronic monomyelocytic leukemia.
Dong Z, Sepulveda H, Arteaga-Vazquez LJ, Blouin C, Fernandez J, Binder M, Chou WC, Tien HF, Patnaik M, Faulkner GJ, Myers SA, Rao A. Dong Z, et al. Among authors: rao a. bioRxiv [Preprint]. 2025 Jan 2:2024.01.30.578015. doi: 10.1101/2024.01.30.578015. bioRxiv. 2025. Update in: Proc Natl Acad Sci U S A. 2025 Jan 7;122(1):e2413302121. doi: 10.1073/pnas.2413302121 PMID: 39803572 Free PMC article. Updated. Preprint.
Dosimetric and On-treatment Clinical Results of a Volumetric-based Skin-sparing Planning Technique for Patients Treated to the Breast and Chest Wall With Pencil-Beam Scanning Proton Therapy.
Rao AD, Goughenour A, Kebede B, Bamberger C, MacLennan G, Castro J, Stephenson L, Negussie A, Seracino S, Wang H, Hetelekidis S, Gao SJ, Majithia L, Chawla A, Parniani A, Wang P, Fan J. Rao AD, et al. Adv Radiat Oncol. 2024 Oct 30;10(2):101653. doi: 10.1016/j.adro.2024.101653. eCollection 2025 Feb. Adv Radiat Oncol. 2024. PMID: 39802863 Free PMC article.
6,204 results